Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Translate Bio, Inc. (TBIO)

37.36   0 (0%) 10-01 09:49
Open: 37.64 Pre. Close: 37.36
High: 37.64 Low: 37.17
Volume: 1,274,907 Market Cap: 2,811(M)
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 22.35 - 22.46 22.46 - 22.56
Low: 21.28 - 21.42 21.42 - 21.55
Close: 21.91 - 22.13 22.13 - 22.35

Technical analysis

as of: 2022-04-29 4:26:45 PM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 27.11     One year: 29.21
Support: Support1: 20.31    Support2: 16.9
Resistance: Resistance1: 23.21    Resistance2: 25.01
Pivot: 22.8
Moving Average: MA(5): 22.23     MA(20): 23.25
MA(100): 25.07     MA(250): 26.1
MACD: MACD(12,26): -0.7     Signal(9): -0.6
Stochastic oscillator: %K(14,3): 38.6     %D(3): 39.4
RSI: RSI(14): 36.9
52-week: High: 28.89  Low: 20.31
Average Vol(K): 3-Month: 23 (K)  10-Days: 23 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ TCBIO ] has closed above bottom band by 22.1%. Bollinger Bands are 48.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.

Headline News

Thu, 11 Aug 2022
Acquisition of TeneoTwo for its clinical-stage T-cell engager completed - AstraZeneca

Thu, 28 Jul 2022
Takeda cuts ties to cancer drug landed in $120M Turnstone deal - FierceBiotech

Tue, 05 Jul 2022
AstraZeneca to Acquire TeneoTwo, For Up To USD1.275 Billion - FinSMEs

Wed, 27 Oct 2021
Newly-Formed Ancora Biotech Will Continue Operations of Teneobio Spin-offs After Successful Acquisition of Teneobio by Amgen - Business Wire

Thu, 05 Aug 2021
Translate Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update - GlobeNewswire

Tue, 03 Aug 2021
Why Translate Bio Stock Soared Today - The Motley Fool

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 50 (M)
% Held by Insiders 0 (%)
% Held by Institutions 28.3 (%)
Shares Short 7 (K)
Shares Short P.Month 17 (K)

Stock Financials

EPS 4.55
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 56.27
Profit Margin (%) 27.1
Operating Margin (%) 39.5
Return on Assets (ttm) 0.6
Return on Equity (ttm) 8.3
Qtrly Rev. Growth 0.6
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 4.8
Operating Cash Flow 657 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio 4.87
PEG Ratio 0
Price to Book value 0.39
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2021-12-14
Ex-Dividend Date 2021-11-29
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.